Professor David O’Neal from St Vincent’s Hospital in Melbourne, Victoria is amongst the first healthcare professionals to prescribe Omnipod DASH to patients. The system allows customers to deliver insulin through customizable basal and bolus amounts with no daily injections and no tubes. Omnipod DASH includes two parts: a sleek, touchscreen Personal Diabetes Manager (PDM) with an intuitive interface, and a waterproof 1, wearable Pod that provides up to 72 hours 2 of continuous insulin therapy. Insulet’s planned launch in Australia is part of its global expansion strategy, which included five additional European and Middle Eastern markets in 2020, as well as Turkey earlier this year. “As the first waterproof, wearable tubeless pump available in this country, Omnipod DASH will offer insulin-requiring Australians the freedom, flexibility, and discretion needed to simplify their diabetes management.” “As part of our ongoing efforts to bring Omnipod technology to more people living with diabetes around the world, we’re excited to announce that Omnipod DASH will soon be available in Australia,” said Bret Christensen, Chief Commercial Officer of Insulet. Insulet expects to begin taking customer orders for Omnipod DASH by the end of August. ACTON, Mass.-( BUSINESS WIRE)-Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented the Omnipod DASH® Insulin Management System (Omnipod DASH) to healthcare providers attending the virtual Australasian Diabetes Congress.
0 kommentar(er)
